Structure via PubChem · Public domain (PubChem)
macitentan
Sign in to saveAlso known as ACT-064992, ACT064992, ACT 064992
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.
Chemical data
- Formula
- C19H20Br2N6O4S
- Molecular weight
- 588.3 g/mol
- IUPAC name
- 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine
- SMILES
- CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
- InChIKey
- JGCMEBMXRHSZKX-UHFFFAOYSA-N
- XLogP
- 3.7
- Polar surface area
- 137 Ų
- H-bond donors
- 2
- H-bond acceptors
- 10
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2010
- Admin. routes
- oral
- Indications
- pulmonary arterial hypertension, idiopathic pulmonary fibrosis, systemic scleroderma, glioblastoma multiforme
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 585.9633483200003
- Has use
- medication
Show 7 more facts
- chemical formula
- C₁₉H₂₀Br₂N₆O₄S
- canonical SMILES
- CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
- World Health Organisation international non-proprietary name
- macitentan
- defined daily dose
- 10
- medical condition treated
- pulmonary hypertension
- Commons category
- Macitentan
- legal status (medicine)
- boxed warning
Sources (7)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Adverse effects
- Mechanism of action
- Endothelin and endothelin receptors
- Role of macitentan
- Pharmacokinetics
- Experimental pharmacokinetics
- References
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.
Macitentan was approved for medical use in the United States in October 2013.
Excerpted from Wikipedia’s “macitentan” article, available under the CC BY-SA 4.0 licence.
Gallery (2)
Available in 11 languages
via Wikidata sitelinks · CC0